登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
ClinicalTrials.gov 上登记的一项肺癌开放试验,由香港大学深圳医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07663630,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Documented histological or cytologic diagnosis of NSCLC with each of the following:
入选标准第 2 条
locally advanced, unresectable, stage III disease (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system); and
入选标准第 3 条
Undergoing major surgery within 4 weeks prior to randomization or planned major surgical procedures during the study.
排除标准第 9 条
Renal disease requiring dialysis or eGFR <30 mL/min/1.73 m².
排除标准第 19 条
measurable disease at time of screening (assessment per RECIST v1.1); and
入选标准第 4 条
Mixed small cell and non-small cell lung cancer histology.
排除标准第 7 条
History of any secondary malignancy in the last 2 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ.
排除标准第 12 条
Any Grade ≥3 pulmonary disease unrelated to underlying malignancy including, but not limited to:
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07663630,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed Informed Consent Documented histological or cytologic diagnosis of NSCLC with each of the following: locally advanced, unresectable, stage III disease (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system); and measurable disease at time of screening (assessment per RECIST v1.1); and must have completed platinum-based chemotherapy concurrent with radiation therapy, within 7 to 42 days prior to the randomization; and no evidence of progression of disease following definitive, platinum-based, concurrent chemoradiation therapy; and must be due to receive consolidation immunotherapy with durvalumab for up to 12 months, with the first dose of blinded study intervention to coincide with the first dose of durvalumab +/- 7 days; and absence of actional genomic mutations (eg, EGFR, ALK). Cachexia defined by Fearon criteria: BMI <20 kg/m2 and involuntary weight loss of >2% within 6 months prior to screening; or Involuntary weight loss of >5% over the past 6 months prior to screening irrespective of BMI Participant has been evaluated and determined that available anticachexic treatments have either been administered with no positive effect or the participant is not suitable for these treatments. Participants who are assessed by the investigator to have an ECOG PS ≤1.排除标准:Exclusion Criteria:
Current active reversible causes of decreased food intake, as determined by the investigator. These causes may include, but are not limited to: NCI CTCAE Grade 3 or 4 oral mucositis Mechanical obstructions interfering with the participant's ability to eat Receiving tube feedings or having an ongoing clinical indication for parenteral nutrition (either total or partial) at the time of screening or randomization. Of note: short-term parenteral nutritional support for the management of acute, transient medical indications is allowed if discontinued prior to randomization. Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification. Cachexia caused by reasons other than NSCLC, as determined by the investigator (eg, severe COPD). Mixed small cell and non-small cell lung cancer histology. Clinically significant ascites that requires medical intervention or underwent a paracentesis within 4 weeks prior to randomization. Undergoing major surgery within 4 weeks prior to randomization or planned major surgical procedures during the study. History of adrenal disorders (e.g. adrenal insufficiency, Cushing syndrome), pituitary adenoma or ectopic ACTH. Chronic use of systemic corticosteroid. History of any secondary malignancy in the last 2 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ. Symptomatic brain metastasis or leptomeningeal disease. Any Grade ≥3 pulmonary disease unrelated to underlying malignancy including, but not limited to: Severe asthma requiring systemic corticosteroids within 30 days prior to first dose of study intervention or not well controlled with low-dose inhaled corticosteroids/long-acting beta-2 agonists. Severe chronic obstructive pulmonary disease requiring supplemental oxygen or systemic corticosteroids. Clinically severe and/or Grade 4 pulmonary emboli within 3 months of the first dose of study intervention. Pulmonary emboli in main or lobar pulmonary arteries are also excluded. Any autoimmune or inflammatory disorders with significant pulmonary parenchymal involvement at time of screening (ie, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc). Renal disease requiring dialysis or eGFR <30 mL/min/1.73 m². History of severe liver disease or cirrhosis, unrelated to metastatic cancer. LFT abnormalities at the time of screening; confirmed by a single repeat test if deemed necessary: AST or ALT level ≥ 3 x ULN (>5 x ULN if liver involvement by the tumor), or total bilirubin level ≥ 1.5 x ULN (For Gilbert's syndrome, direct bilirubin > ULN is exclusionary). Left ventricular ejection fraction <50% on screening echocardiogram (or MUGA scan).
引自 ClinicalTrials.gov, NCT07663630, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07663630,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。